Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. More Details
Excellent balance sheet with solid track record.
Share Price & News
How has Laurus Labs's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LAURUSLABS is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: LAURUSLABS's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: LAURUSLABS exceeded the Indian Pharmaceuticals industry which returned 47.5% over the past year.
Return vs Market: LAURUSLABS exceeded the Indian Market which returned 65.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Laurus Labs's share price compared to the market and industry in the last 5 years?
Simply Wall St News
10 hours ago | Simply Wall StWe Think That There Are Issues Underlying Laurus Labs' (NSE:LAURUSLABS) Earnings
1 day ago | Simply Wall StShould You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
1 month ago | Simply Wall StLaurus Labs Limited's (NSE:LAURUSLABS) Stock Been Rising: Are Strong Financials Guiding The Market?
Is Laurus Labs undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: LAURUSLABS (₹481.25) is trading above our estimate of fair value (₹394.02)
Significantly Below Fair Value: LAURUSLABS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LAURUSLABS is poor value based on its PE Ratio (26.8x) compared to the IN Pharmaceuticals industry average (23x).
PE vs Market: LAURUSLABS is poor value based on its PE Ratio (26.8x) compared to the Indian market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: LAURUSLABS is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: LAURUSLABS is overvalued based on its PB Ratio (10.1x) compared to the IN Pharmaceuticals industry average (2.8x).
How is Laurus Labs forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LAURUSLABS's forecast earnings growth (15% per year) is above the savings rate (6.8%).
Earnings vs Market: LAURUSLABS's earnings (15% per year) are forecast to grow slower than the Indian market (23.2% per year).
High Growth Earnings: LAURUSLABS's earnings are forecast to grow, but not significantly.
Revenue vs Market: LAURUSLABS's revenue (16.6% per year) is forecast to grow faster than the Indian market (13.4% per year).
High Growth Revenue: LAURUSLABS's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LAURUSLABS's Return on Equity is forecast to be high in 3 years time (22.7%)
How has Laurus Labs performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LAURUSLABS has a high level of non-cash earnings.
Growing Profit Margin: LAURUSLABS's current net profit margins (20.3%) are higher than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: LAURUSLABS's earnings have grown significantly by 43.1% per year over the past 5 years.
Accelerating Growth: LAURUSLABS's earnings growth over the past year (285.3%) exceeds its 5-year average (43.1% per year).
Earnings vs Industry: LAURUSLABS earnings growth over the past year (285.3%) exceeded the Pharmaceuticals industry 39.2%.
Return on Equity
High ROE: LAURUSLABS's Return on Equity (37.8%) is considered high.
How is Laurus Labs's financial position?
Financial Position Analysis
Short Term Liabilities: LAURUSLABS's short term assets (₹30.7B) exceed its short term liabilities (₹24.6B).
Long Term Liabilities: LAURUSLABS's short term assets (₹30.7B) exceed its long term liabilities (₹6.9B).
Debt to Equity History and Analysis
Debt Level: LAURUSLABS's debt to equity ratio (50.6%) is considered high.
Reducing Debt: LAURUSLABS's debt to equity ratio has reduced from 119.7% to 50.6% over the past 5 years.
Debt Coverage: LAURUSLABS's debt is well covered by operating cash flow (55.7%).
Interest Coverage: LAURUSLABS's interest payments on its debt are well covered by EBIT (20.1x coverage).
What is Laurus Labs's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: LAURUSLABS's dividend (0.41%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.42%).
High Dividend: LAURUSLABS's dividend (0.41%) is low compared to the top 25% of dividend payers in the Indian market (1.77%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, LAURUSLABS has been paying a dividend for less than 10 years.
Growing Dividend: LAURUSLABS's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (10.9%), LAURUSLABS's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: LAURUSLABS's dividends in 3 years are forecast to be thoroughly covered by earnings (9.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Satyanarayana Chava (59 yo)
Dr. Satyanarayana Chava, PhD, M.sc., has been the Chief Executive Officer of Laurus Labs Limited (also known as Laurus Labs Private Limited and Aptuit Laurus Private Limited) since June 2007 and has been i...
CEO Compensation Analysis
Compensation vs Market: Satyanarayana's total compensation ($USD1.08M) is above average for companies of similar size in the Indian market ($USD670.04K).
Compensation vs Earnings: Satyanarayana's compensation has been consistent with company performance over the past year.
Experienced Board: LAURUSLABS's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LAURUSLABS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Laurus Labs Limited's company bio, employee growth, exchange listings and data sources
- Name: Laurus Labs Limited
- Ticker: LAURUSLABS
- Exchange: NSEI
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹263.660b
- Shares outstanding: 536.60m
- Website: https://www.lauruslabs.com
Number of Employees
- Laurus Labs Limited
- Serene Chambers
- 2nd Floor
Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. It o...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/06 12:41|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.